Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million
WuXi Biologics Congratulates Tychan on First-in-Class Monoclonal Antibody for Yellow Fever after Record 7 Months of Development
WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics
WuXi Biologics and ABL Bio Enter an Exclusive Development and Clinical Manufacturing Partnership for Multiple Bispecific Antibodies
WuXi Biologics Congratulates Tychan on Completing Human Safety Studies for the First-in-Class Zika Virus Antibody in Record Speed